尼日利亚癫痫的患病率、特征和治疗结果:系统回顾和荟萃分析

IF 3.4 3区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
Nicholas Aderinto, Bonaventure Ukoaka, Gbolahan Olatunji, Emmanuel Kokori, Samson Afolabi, Adetola Emmanuel Babalola, Ismaila Yusuf, Ikponmwosa Jude Ogieuhi, Abdulrahmon Moradeyo, Opabode Muntaqim Obasanjo, Adefusi Oluwakorede, Oluwatobi Omoworare, Yewande Abigail Adebayo
{"title":"尼日利亚癫痫的患病率、特征和治疗结果:系统回顾和荟萃分析","authors":"Nicholas Aderinto, Bonaventure Ukoaka, Gbolahan Olatunji, Emmanuel Kokori, Samson Afolabi, Adetola Emmanuel Babalola, Ismaila Yusuf, Ikponmwosa Jude Ogieuhi, Abdulrahmon Moradeyo, Opabode Muntaqim Obasanjo, Adefusi Oluwakorede, Oluwatobi Omoworare, Yewande Abigail Adebayo","doi":"10.1186/s40001-025-02980-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Epilepsy poses a significant health burden globally. In Nigeria, limited access to healthcare and potential regional variations in risk factors necessitate an understanding of epilepsy's characteristics and treatment. This study addresses this gap by conducting a systematic review and meta-analysis to investigate the prevalence, demographic variations, seizure types, and treatment modalities of epilepsy in Nigeria.</p><p><strong>Methods: </strong>A systematic review was conducted following PRISMA guidelines (CRD42024549637). We searched PubMed, Google Scholar, and other databases (6 total) from inception to February 2024 using a combination of MeSH terms and keywords related to epilepsy and Nigeria. Studies included observational studies, clinical trials, and those reporting on the prevalence, characteristics, and management of epilepsy in Nigeria. We excluded studies outside Nigeria, lacking relevant data, or non-research materials. Two reviewers screened titles/abstracts and full texts for eligibility. Data extraction included demographics, sample size, location, seizure type, and treatment outcomes. The JBI tool assessed study quality. We did systematic synthesis and meta-analysis for prevalence.</p><p><strong>Results: </strong>The prevalence of epilepsy ranged from 0.45 to 36.09%. The overall pooled prevalence of epilepsy is 14.21% (95% CI 1.56-36.16) among all age group patients. Children presented with the highest prevalence (36.09%), followed by adults (11.85%) and in combine adult and children studies (3.16%). The South-South zone had the highest prevalence (21.73%), while the North-Central zone had the lowest (0.47%). Generalized tonic-clonic seizures were the most common type reported (76.9-83.13%). Carbamazepine was a frequent first-line treatment, with some studies indicating good results, particularly in children. Monotherapy was generally preferred.</p><p><strong>Conclusion: </strong>Epilepsy prevalence in Nigeria varies considerably. Children and the South-South zone appear to be more affected. Carbamazepine is a common first-line treatment. Further research is required to explore underlying causes, optimal treatment strategies, and adherence challenges.</p>","PeriodicalId":11949,"journal":{"name":"European Journal of Medical Research","volume":"30 1","pages":"986"},"PeriodicalIF":3.4000,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12533339/pdf/","citationCount":"0","resultStr":"{\"title\":\"Prevalence, characteristics, and treatment outcomes of epilepsy in Nigeria: a systematic review and meta-analysis.\",\"authors\":\"Nicholas Aderinto, Bonaventure Ukoaka, Gbolahan Olatunji, Emmanuel Kokori, Samson Afolabi, Adetola Emmanuel Babalola, Ismaila Yusuf, Ikponmwosa Jude Ogieuhi, Abdulrahmon Moradeyo, Opabode Muntaqim Obasanjo, Adefusi Oluwakorede, Oluwatobi Omoworare, Yewande Abigail Adebayo\",\"doi\":\"10.1186/s40001-025-02980-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Epilepsy poses a significant health burden globally. In Nigeria, limited access to healthcare and potential regional variations in risk factors necessitate an understanding of epilepsy's characteristics and treatment. This study addresses this gap by conducting a systematic review and meta-analysis to investigate the prevalence, demographic variations, seizure types, and treatment modalities of epilepsy in Nigeria.</p><p><strong>Methods: </strong>A systematic review was conducted following PRISMA guidelines (CRD42024549637). We searched PubMed, Google Scholar, and other databases (6 total) from inception to February 2024 using a combination of MeSH terms and keywords related to epilepsy and Nigeria. Studies included observational studies, clinical trials, and those reporting on the prevalence, characteristics, and management of epilepsy in Nigeria. We excluded studies outside Nigeria, lacking relevant data, or non-research materials. Two reviewers screened titles/abstracts and full texts for eligibility. Data extraction included demographics, sample size, location, seizure type, and treatment outcomes. The JBI tool assessed study quality. We did systematic synthesis and meta-analysis for prevalence.</p><p><strong>Results: </strong>The prevalence of epilepsy ranged from 0.45 to 36.09%. The overall pooled prevalence of epilepsy is 14.21% (95% CI 1.56-36.16) among all age group patients. Children presented with the highest prevalence (36.09%), followed by adults (11.85%) and in combine adult and children studies (3.16%). The South-South zone had the highest prevalence (21.73%), while the North-Central zone had the lowest (0.47%). Generalized tonic-clonic seizures were the most common type reported (76.9-83.13%). Carbamazepine was a frequent first-line treatment, with some studies indicating good results, particularly in children. Monotherapy was generally preferred.</p><p><strong>Conclusion: </strong>Epilepsy prevalence in Nigeria varies considerably. Children and the South-South zone appear to be more affected. Carbamazepine is a common first-line treatment. Further research is required to explore underlying causes, optimal treatment strategies, and adherence challenges.</p>\",\"PeriodicalId\":11949,\"journal\":{\"name\":\"European Journal of Medical Research\",\"volume\":\"30 1\",\"pages\":\"986\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-10-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12533339/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Medical Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s40001-025-02980-y\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40001-025-02980-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:癫痫在全球范围内构成了重大的健康负担。在尼日利亚,获得医疗保健的机会有限,风险因素可能存在区域差异,因此有必要了解癫痫的特点和治疗方法。本研究通过进行系统回顾和荟萃分析来调查尼日利亚癫痫的患病率、人口统计学差异、发作类型和治疗方式,从而解决了这一差距。方法:按照PRISMA指南(CRD42024549637)进行系统评价。我们检索了PubMed、b谷歌Scholar和其他数据库(共6个),从成立到2024年2月,使用与癫痫和尼日利亚相关的MeSH术语和关键词组合。研究包括观察性研究、临床试验以及关于尼日利亚癫痫患病率、特征和管理的报告。我们排除了尼日利亚以外缺乏相关数据或非研究材料的研究。两名审稿人对标题/摘要和全文进行筛选。数据提取包括人口统计、样本量、地点、癫痫发作类型和治疗结果。JBI工具评估研究质量。我们对患病率进行了系统的综合和荟萃分析。结果:癫痫患病率为0.45% ~ 36.09%。所有年龄组患者癫痫的总总患病率为14.21% (95% CI 1.56-36.16)。儿童患病率最高(36.09%),其次是成人(11.85%),成人和儿童联合调查(3.16%)。南南区患病率最高(21.73%),中北部患病率最低(0.47%)。全身性强直-阵挛性发作是最常见的类型(76.9-83.13%)。卡马西平是常用的一线治疗,一些研究表明效果良好,特别是对儿童。一般首选单药治疗。结论:尼日利亚的癫痫患病率差异很大。儿童和南南地区似乎受到的影响更大。卡马西平是常用的一线治疗药物。需要进一步的研究来探索潜在的原因、最佳的治疗策略和依从性挑战。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Prevalence, characteristics, and treatment outcomes of epilepsy in Nigeria: a systematic review and meta-analysis.

Prevalence, characteristics, and treatment outcomes of epilepsy in Nigeria: a systematic review and meta-analysis.

Prevalence, characteristics, and treatment outcomes of epilepsy in Nigeria: a systematic review and meta-analysis.

Prevalence, characteristics, and treatment outcomes of epilepsy in Nigeria: a systematic review and meta-analysis.

Background: Epilepsy poses a significant health burden globally. In Nigeria, limited access to healthcare and potential regional variations in risk factors necessitate an understanding of epilepsy's characteristics and treatment. This study addresses this gap by conducting a systematic review and meta-analysis to investigate the prevalence, demographic variations, seizure types, and treatment modalities of epilepsy in Nigeria.

Methods: A systematic review was conducted following PRISMA guidelines (CRD42024549637). We searched PubMed, Google Scholar, and other databases (6 total) from inception to February 2024 using a combination of MeSH terms and keywords related to epilepsy and Nigeria. Studies included observational studies, clinical trials, and those reporting on the prevalence, characteristics, and management of epilepsy in Nigeria. We excluded studies outside Nigeria, lacking relevant data, or non-research materials. Two reviewers screened titles/abstracts and full texts for eligibility. Data extraction included demographics, sample size, location, seizure type, and treatment outcomes. The JBI tool assessed study quality. We did systematic synthesis and meta-analysis for prevalence.

Results: The prevalence of epilepsy ranged from 0.45 to 36.09%. The overall pooled prevalence of epilepsy is 14.21% (95% CI 1.56-36.16) among all age group patients. Children presented with the highest prevalence (36.09%), followed by adults (11.85%) and in combine adult and children studies (3.16%). The South-South zone had the highest prevalence (21.73%), while the North-Central zone had the lowest (0.47%). Generalized tonic-clonic seizures were the most common type reported (76.9-83.13%). Carbamazepine was a frequent first-line treatment, with some studies indicating good results, particularly in children. Monotherapy was generally preferred.

Conclusion: Epilepsy prevalence in Nigeria varies considerably. Children and the South-South zone appear to be more affected. Carbamazepine is a common first-line treatment. Further research is required to explore underlying causes, optimal treatment strategies, and adherence challenges.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
European Journal of Medical Research
European Journal of Medical Research 医学-医学:研究与实验
CiteScore
3.20
自引率
0.00%
发文量
247
审稿时长
>12 weeks
期刊介绍: European Journal of Medical Research publishes translational and clinical research of international interest across all medical disciplines, enabling clinicians and other researchers to learn about developments and innovations within these disciplines and across the boundaries between disciplines. The journal publishes high quality research and reviews and aims to ensure that the results of all well-conducted research are published, regardless of their outcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信